Intellia Therapeutics (NTLA) Expected to Announce Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) is expected to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Intellia Therapeutics to post earnings of ($0.99) per share and revenue of $12.1730 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Intellia Therapeutics Stock Up 4.1%

NASDAQ NTLA opened at $13.16 on Tuesday. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -3.08 and a beta of 2.10. The business has a 50-day moving average price of $11.51 and a 200-day moving average price of $12.97. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.25.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on NTLA. Robert W. Baird set a $7.00 price target on Intellia Therapeutics in a research note on Tuesday, January 27th. William Blair downgraded shares of Intellia Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, October 27th. Truist Financial reaffirmed a “buy” rating and set a $14.00 target price (down from $25.00) on shares of Intellia Therapeutics in a research note on Monday, November 10th. Tudor Pickering set a $14.50 price target on shares of Intellia Therapeutics in a report on Tuesday, October 28th. Finally, Barclays decreased their price target on shares of Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating on the stock in a research note on Friday, November 7th. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $17.48.

Insiders Place Their Bets

In other news, EVP Birgit C. Schultes sold 8,508 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $78,358.68. Following the transaction, the executive vice president owned 98,533 shares of the company’s stock, valued at approximately $907,488.93. The trade was a 7.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO John M. Leonard sold 34,146 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $314,484.66. Following the sale, the chief executive officer owned 1,013,339 shares in the company, valued at $9,332,852.19. The trade was a 3.26% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 53,051 shares of company stock valued at $488,600 over the last ninety days. 3.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of NTLA. Virtu Financial LLC purchased a new stake in shares of Intellia Therapeutics in the fourth quarter valued at $245,000. Invesco Ltd. grew its holdings in Intellia Therapeutics by 5.8% during the 4th quarter. Invesco Ltd. now owns 433,290 shares of the company’s stock valued at $3,895,000 after purchasing an additional 23,870 shares during the last quarter. Axxcess Wealth Management LLC raised its position in Intellia Therapeutics by 20.1% in the 4th quarter. Axxcess Wealth Management LLC now owns 21,399 shares of the company’s stock worth $192,000 after purchasing an additional 3,583 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in Intellia Therapeutics in the fourth quarter worth about $90,000. Finally, XTX Topco Ltd bought a new stake in Intellia Therapeutics in the fourth quarter worth about $402,000. Institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.